Amyotrophic Lateral Sclerosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Amyotrophic Lateral Sclerosis Treatment Market is segmented By Treatment Type (Medication and Others), By Distribution Channel and Geography.

Market Snapshot

Amyotrophic Lateral Sclerosis Treatment Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Amyotrophic Lateral Sclerosis Treatment is expected to register a CAGR of 5.5% during the forecast period. This is attributing the rising prevalence of amyotrophic lateral sclerosis diseases and the growing geriatric population worldwide. As per the Centers for Disease Control and Prevention, in 2016, amyotrophic lateral sclerosis (ALS) is a common neuromuscular disease globally and around 14000-15000 individuals have experienced (ALS) in the United States. In addition, according to the National Institute of Neurological Disorder and Stroke, Sporadic ALS is the most common form type contributed to 90% of cases in the United States and Familial ALS contributed 10%. Thus, these populations are going to promote the demand for treatment of this disorder. Although there is no permanent solution for this disorder, stem cell therapies and medications will prevent complications and decline the disease progression. Moreover, the growing adoption of a sedentary lifestyle will be going to increase the chances of developing this disorder among the aging population which further creates a lucrative opportunity for major players to work for novel therapeutics approaches and treatments. However, less awareness and high costs associated with the treatment may hamper the market to a certain extent.

Scope of the Report

Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder and fatal disease that affects nerve cells in the neuron and spinal control which controls voluntary muscle movement in the human body. This disorder affects neurons which results in blockage of messages between muscles and brain.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Medications in Amyotrophic Lateral Sclerosis Treatment (ALS) is Estimated to Witness a Healthy Growth in Future.

Medications in amyotrophic lateral sclerosis treatment are estimated to witness healthy growth in the future. Medications such as riluzole and edaravone are the only two drugs that are approved by the Food and Drug Administration (FDA) to treat ALS. In addition, the FDA also approved NeuRx Diaphragm Pacing System wherein implanted electrodes and batteries are used to contract diaphragm in the ALS population. Moreover, medications help in relieving symptoms, spasticity, panic attacks, pain, and depression. Thus, the rising prevalence of ALS diseases worldwide will be going to trigger the demand for these drugs for treatment and thereby drives the segment growth.

Furthermore, several initiatives associated with amyotrophic lateral sclerosis treatment will also boost the overall market.

img

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Amyotrophic Lateral Sclerosis Treatment due to the rising prevalence of Amyotrophic Lateral Sclerosis diseases, the growing demand for ALS drugs, increasing healthcare expenditure, and well- established healthcare infrastructure, favorable reimbursement policies, and technological advancements. Furthermore, the presence of the geriatric population is more likely to have these disorders. As per the Centers for Disease Control and Prevention (CDC) with Agency for Toxic Substances and Disease Registry (ATSDR) said the majority of the population who are above 50 years more prone to have this disorder and thus expected to fuel the Amyotrophic Lateral Sclerosis Treatment in this region.

geography amyotrophic lateral.png

Competitive Landscape

The Amyotrophic Lateral Sclerosis Treatment is moderately competitive and consists of several major players. Some of the companies which are playing crucial role in the market studied are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F.Hoffmann-La Roche AG.

Recent Developments

 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Amyotrophic Lateral Sclerosis

      2. 4.2.2 Growing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Medication

      2. 5.1.2 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Mitsubishi Tanabe Pharma Corporation

      2. 6.1.2 Sun Pharmaceutical Industries Ltd.

      3. 6.1.3 CORESTEM, Inc

      4. 6.1.4 BrainStorm Cell Limited

      5. 6.1.5 Amylyx Pharmaceuticals Inc.

      6. 6.1.6 AB Science

      7. 6.1.7 Ionis Pharmaceuticals

      8. 6.1.8 Biohaven Pharmaceutical

      9. 6.1.9 Biogen

      10. 6.1.10 F.Hoffmann-La Roche AG

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Amyotrophic Lateral Sclerosis Treatment Market market is studied from 2018 - 2026.

The Amyotrophic Lateral Sclerosis Treatment Market is growing at a CAGR of 6.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Mitsubishi Tanabe Pharma Corporation, CORESTEM, Inc, BrainStorm Cell Limited, Sun Pharmaceutical Industries Ltd., Amylyx Pharmaceuticals Inc. are the major companies operating in Amyotrophic Lateral Sclerosis Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!